Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1991-07-12
1993-04-06
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 46, 514 47, 514 49, 514 50, 514 51, 514256, 514274, 514885, A01N 4304, A01N 4354
Patent
active
052004007
ABSTRACT:
Method for inhibiting acute rejection of a transplanted organ or tissue by a recipient mammal that includes the steps of administering to the mammal a compound which causes selective sensitization of the alloreactive lymphocytes of the transplant recipient that are involved in the rejection process to a toxin; and exposing the mammal to the toxin to selectively destroy the sensitized alloreactive lymphocytes to a greater extent than non-sensitized cells of the mammal. This method induces donor specific tolerance in the transplant recipient, i.e., acceptance of the new organ or tissue without suppression of the rest of the recipient's normal immune system.
REFERENCES:
patent: 4894364 (1990-01-01), Greer
patent: 5028594 (1991-07-01), Carson
Mishell et al Selected Methods in Cellular Immunology, pp. 238-239 1986.
Roitt et al Immunology p. 24.8 1985.
Goodman et al The Pharmacological Basis of Therapeutics pp. 1268-1276 1985.
Teramoto et al "DNA Synthesis . . . " Biosis Abst. #90096965 of Transplantation 50(2):199-201 1990.
B. Shutte et al., "Studies With Anti-bromodeoxyuridine Antibodies: II. Simultaneous Immunocytochemical Detection of Antigen Expression and DNA Synthesis by In Vivo Labeling of Mouse Intestinal Mucosa", 1986.
B. Schutte et al., "An Improved Method for the Immunocytochemical Detection of Bromodeoxyuridine Labeled Nuclei Using Flow Cytometry", vol. 8, 1987, pp. 372-376.
M. Pallavicini et al., "Cytokinetic Properties of Asynchronous and Cytosine Arabinoside Perturbed Murine Tumors Measured by Simultaneous Bromodeoxyuridine/DNA Analyses", Cytometry, vol. 6, 1985, pp. 602-610.
Kinsella, Timothy J., M.D. et al., "The Use of Halogenated Thymidine Analogs as Clinical Radiosensitizers: Rationale, Current Status, and Future Prospects: Non-Hypoxic Cell Sensitizers", Radiation Oncology, vol. 10, No. 8, Aug. 1984, pp. 1399-1406.
Kinsella, Timothy J. M.D. et al., "A Phase I Study of Intermittent Intravenous bromodeoxyuridine (BUdR) With Conventional Fractioned Irradiation", Radiation Oncology, vol. 10, No. 1, Jan. 1984, pp. 69-76.
T. Aoyama et al., "Effect of Halogenated Pyrimidines on Radiosensitivity of Mouse Strain L Cells and Their Radioresistant Variant", Journal of Radiation Research, vol. 5, No. 1, Mar., 1964, pp. 39-48.
F. Dolbeare et al., "Flow cytometic measurement of total DNA content and incorporated bromodeoxyuridine", Proc. Natl. Acad. Sci., vol. 80, Sep., 1983, pp. 5573-5577.
Kinsella, Timothy J. et al., "Continuous Intravenous Infusions of Bromodeoxyuridine As a Clinical Radiosensitizer", Journal of Clinical Oncology, vol. 2, No. 10, Oct. 1984, pp. 1144-1150.
J. Kriss et al., "The Fate of 5-Bromodeoxyuridine, 5-Bromodeoxycytidine, and 5-Iododeoxycytidine in Man", Departments of Medicine and Radiology, Stanford University School of Medicine, pp. 260-261 1962.
Kinsella, Timothy J., M.D. et al., "A Phase I Study of Intravenous Idodeoxyuridine As a Clinical Radiosensitizer", Radiation Oncology, vol. 11, No. 11, Nov. 1985, pp. 1941-1946.
T. Ruers et al., "Cellular Proliferation At The Side Of Organ Allografts And The Influence Of Immunosuppresive Therapy", Transplantation, vol. 50, No. 4, Oct. 1990, pp. 568-572.
K. Sano et al., "A Therapy for Malignant Brain Tumors, Using Radiosensitizer (Bromouridine-Antometabolite-Continuous Intra-Arterial Infusion-Radiation Therapy)", University of Tokyo, p. 23 1972.
Kinsella, Timothy J., M.D., "Enhancement of X Ray Induced DNA Damage by Pre-Treatment With Halogenated Pyrimidine Analogs", I.J. Radiation Oncology, vol. 13, No. 5, May 1987, pp. 733-739.
Clouse Melvin E.
Teramoto Kenichi
Hook Gregory
New England Deaconess Hospital Corporation
Waddell Frederick E.
LandOfFree
Method for inhibiting allograft rejection using photoactivatable does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inhibiting allograft rejection using photoactivatable, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inhibiting allograft rejection using photoactivatable will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-536801